Frequently asked questions

Two sites can draw different curves because they use different formulations, absorption rates or assumptions about how doses overlap. The shape alone does not tell you which is more accurate.

Check the compound’s model notes and units. Changing your schedule changes the example; it does not fit the model to your body. Read a curve.

There is no schedule the plotter can certify as safe. Dose spacing or a smoother line does not establish lower health risk. Effects on the heart, hormones and other systems need evidence beyond a concentration curve.

The cycle guide explains why duration alone is not a safety score and what information matters in a clinical discussion.

A drug curve cannot give you a guaranteed negative-test date. Tests can look for metabolites or markers rather than the parent drug, and methods and sampling conditions differ.

The detection reference explains these distinctions. A study’s last positive sample is an observation from that study, not a universal countdown.

Absorption and overlapping doses can both change the shape. Medicine may still be entering the bloodstream after an injection, while a later dose adds to what remains from earlier ones. The curve is not simply a countdown from the moment of injection.

Half-life describes a stage of the decline under particular assumptions. On a normalized chart, 100% means that curve’s peak—not the whole dose still being present. Model explanations.

Match testing to the product and the clinical question. Formulation, time since the last dose and the test method can change what a result means. Record those details with your results.

The Endocrine Society guideline addresses testosterone treatment in men with hypogonadism and uses formulation-specific monitoring. The peak/trough explorer illustrates a model interval; it does not schedule a personal blood draw.

Send the name through the contact form, along with the exact product or formulation and any useful study links.

We review the evidence before choosing a model. Some entries can use a labelled estimate; others, such as mixtures, need a different explanation. A request does not automatically create a concentration curve.

Use the curve to explore timing, not to predict your blood test. It calculates an example from fixed model inputs. A published study model, a researched estimate and an older catalog assumption do not carry the same certainty.

Open the compound’s model details to see its source, formulation and limits. How the models work.

Symptoms alone cannot confirm that estradiol is too low. If symptoms develop while using an aromatase inhibitor, discuss the medicine, amount, timing and appropriate testing with a clinician rather than guessing from a plot.

There is no reliable “wait this many days” recovery rule for everyone. The AI timing guide explains what these medicines change and why a testosterone curve cannot choose an AI dose.

Use the units and reference interval on your laboratory report, with clinical interpretation of the result. A population range is not a personal target.

The cypionate and enanthate study curves exclude your body’s own testosterone. They cannot be compared directly with a total-testosterone blood test. Reference bands are therefore not shown on those models. Reading bloodwork.

A warning means the catalog has a flagged concern for that combination. Read its details and discuss the actual medicines with a clinician or pharmacist.

No warning does not mean a stack is safe. The warning system is not a complete interaction checker, and adding a combination to the plotter does not validate its use. Interaction guide.

There is no universal start date that can be calculated from a half-life. The substances used, exposure history, current medicines, symptoms and fertility goals all matter.

The PCT evidence guide explains what studies have measured. Use the recovery reference to organize a clinical discussion, not to generate a self-treatment schedule.

The recovery reference explains research after anabolic-steroid use and provides questions for a clinical discussion. It does not generate a medication course or an earliest start date.

Hormone levels, symptoms and fertility can recover differently. A falling drug curve does not measure any of those outcomes.

Yes, suppression has been measured in human research. In a short placebo-controlled ligandrol study, total testosterone decreased with increasing dose. That does not establish a dependable suppression ranking for every SARM or an equivalent dose compared with steroids. Original study.

The SARM guide separates the available human findings from animal results and marketing claims.

Yes, but choose the view that matches your question. In the main plotter, rows for the same compound are added together. “Split phases” shows each row’s contribution to that combined schedule.

Use protocol comparison for separate preset examples. A smoother line or similar peak does not establish equal effects or a preferred regimen.

Changing the interval changes how modelled doses overlap. Closer spacing can change the peaks and dips in the example, but a smoother curve does not prove fewer side effects or better results.

For testosterone cypionate and enanthate, the plotted contribution excludes natural testosterone. Compare timing without treating the result as a blood-test prediction or prescription.